Answers are grounded in this paper and cite their sources.
Benign prostatic hyperplasia (BPH) is an age-related condition strongly associated with androgen signaling, chronic inflammation, and dysregulated apoptosis. This study evaluated the antiandrogenic, anti-inflammatory, and proapoptotic effects of β-sitosterol in a testosterone-induced BPH model in orchiectomized Wistar rats. BPH was induced by testosterone propionate (TP) administration. Animals were treated with β-sitosterol, dutasteride, or their combination. Prostate weight, the prostate index, plasma testosterone (TST) and dihydrotestosterone (DHT), and their ratio, the levels of interleukin-1β (IL-1β) and interleukin-6 (IL-6), histopathological changes, and the ratio of BCL2-associated X protein (Bax) to B-cell lymphoma 2 protein (Bcl-2) were assessed. β-Sitosterol significantly increased the TST/DHT ratio compared with the untreated BPH group. However, this change was not accompanied by significant reductions in prostate weight or prostate index. Furthermore, its effects on inflammatory cytokines and apoptosis-related markers did not reach statistical significance following monotherapy. These findings support the further investigation of β-sitosterol as a potential complementary approach to BPH management, rather than as an equivalent alternative to established pharmacological treatments, including through optimized formulations or combinations with other bioactive compounds.
No takes yet. Share an insight, caveat, or question.
Buț et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: